Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis

Drugs in Development for Relapsing Multiple Sclerosis

(2013) Rehiana Ali et al.   DRUGS

Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance

(2013) Ellen Lu et al.   Expert Review of Neurotherapeutics

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Natalizumab treatment during pregnancy - effects on the neonatal immune system

(2012) H. Schneider et al.   ACTA NEUROLOGICA SCANDINAVICA

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

(2012) Celia Oreja-Guevara et al.   BMC Neurology

Integrin signalling and function in immune cells

(2012) Yanbo Zhang et al.   IMMUNOLOGY

Multiple sclerosis

(2012) Alyssa Nylander et al.   JOURNAL OF CLINICAL INVESTIGATION

Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS

(2012) Laura J. Balcer et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Natural, innate improvements in multiple sclerosis disability

(2012) Helen Tremlett et al.   Multiple Sclerosis Journal

Prediction of antibody persistency from antibody titres to natalizumab

(2012) Poul Erik H Jensen et al.   Multiple Sclerosis Journal

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

(2012) Aaron E Miller et al.   Multiple Sclerosis Journal

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

(2012) Anke Vennegoor et al.   Multiple Sclerosis Journal

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

(2012) M Lundkvist et al.   Multiple Sclerosis Journal

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis

(2012) Clara de Andrés et al.   PLoS One

Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis

(2012) Thomas F. Benkert et al.   PLoS One

Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis

(2012) Lars Börnsen et al.   PLoS One

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Molly R. Perkins et al.   PLoS Pathogens

Best practice in the use of natalizumab in multiple sclerosis

(2012) Óscar Fernández   Therapeutic Advances in Neurological Disorders

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

(2012) Stephanie R. Earnshaw et al.   Applied Health Economics and Health Policy

Natalizumab and Impedance of the Homing of CD34+ Hematopoietic Progenitors

(2011) Christian Saure   ARCHIVES OF NEUROLOGY

Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis

(2011) Sara Olofsson et al.   BIODRUGS

Fingolimod

(2011) Lesley J. Scott   CNS DRUGS

Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis

(2011) Henrik Gensicke et al.   CNS DRUGS

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis

(2011) Raquel Planas et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

(2011) G. Borriello et al.   EUROPEAN JOURNAL OF NEUROLOGY

Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients

(2011) Mario Skarica et al.   JOURNAL OF NEUROIMMUNOLOGY

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

(2011) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

(2011) Kerstin Hellwig et al.   Multiple Sclerosis Journal

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

(2011) Carolina Holmén et al.   Multiple Sclerosis Journal

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

(2010) Joseph R. Berger et al.   ANNALS OF NEUROLOGY

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Evolution of Nevi During Treatment With Natalizumab

(2010) Emeline Castela et al.   ARCHIVES OF DERMATOLOGY

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

(2010) Augusto Miravalle et al.   ARCHIVES OF NEUROLOGY

CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function

(2010) D Jing et al.   BONE MARROW TRANSPLANTATION

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis

(2010) Jessica Sharac et al.   DRUGS

Natalizumab treatment reduces endothelial activity in MS patients

(2010) Alban Millonig et al.   JOURNAL OF NEUROIMMUNOLOGY

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

(2010) Chen S Tan et al.   LANCET NEUROLOGY

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months

(2010) Begoña Oliver et al.   Multiple Sclerosis Journal

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

(2010) Fredrik Piehl et al.   NEUROLOGICAL SCIENCES

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

(2009) Richard A Rudick et al.   LANCET NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells

(2009) P. Kivisakk et al.   NEUROLOGY

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

(2009) Ray Gani et al.   PHARMACOECONOMICS

Central Nervous System Immune Surveillance

(2008) Burkhard Becher   ARCHIVES OF NEUROLOGY

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

(2008) H. Bonig et al.   BLOOD

Disease-Modifying Agents for Multiple Sclerosis

(2008) Til Menge et al.   DRUGS

Induction of systemic TNFα in Natalizumab-treated multiple sclerosis

(2008) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden

(2008) G Kobelt et al.   Multiple Sclerosis Journal

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY

More on Melanoma with Transdifferentiation

(2008)   NEW ENGLAND JOURNAL OF MEDICINE